TY  - JOUR
T1  - Role of glutamine versus placebo in prevention of acute gastrointestinal toxicity in pelvic radiotherapy: A randomized control study
A1  - Kazi Manir
A1  - Bhadra Kallol
A1  - Kumar Gaurav
A1  - Adhikari Arnab
A1  - Manna Amitabha
A1  - Sarkar Shaymal
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2014
VL  - 3
IS  - 6
DO  - 10.4103/2278-0513.142637
SP  - 508
EP  - 513
N2  - Context: Nausea, vomiting, diarrhoea, abdominal cramping, ano-proctitis are common acute gastrointestinal (GI) toxicities during pelvic radiotherapy (RT), having important impact on treatment outcome. Glutamine has a major role in mucosal growth and function. This phase III study is conducted to evaluate the role of prophylactic glutamine supplementation in prevention of acute GI toxicities during pelvic RT. Materials and Methods: Eighty five nonmetastatic patients with pelvic malignancy needing pelvic RT are included in this double blind randomized control trial. During RT 42 patients (Arm A) received 10 g glutamine oral supplementation 1 h before every RT fraction. Forty three patients received glycine as placebo (Arm B) in same schedule. Patients were assessed weekly for common acute RT induced GI toxicities. Toxicities were graded according to Common Terminology Criteria for Adverse Events version 4.02. Results: Two arms were well balanced with all baseline parameters. Median age was 57. 56.47% (n = 48) patients had cervical cancer. There was no significant difference between two arms in grade wise incidence of any of the GI toxicities. Trends of diarrhoea during weekly assessments also similar in both arms. Conclusion: There is no significant beneficial effect of glutamine during pelvic RT. As per our study data and our dose schedule glutamine should not be indicated in pelvic RT.
UR  - https://ccij-online.org/article/role-of-glutamine-versus-placebo-in-prevention-of-acute-gastrointestinal-toxicity-in-pelvic-radiotherapy:-a-randomized-control-study-285
ER  -